Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1306 to 1320 of 2183 results for guidelines

  1. What factors encourage uptake of, and adherence to, an exercise referral scheme? Factors to consider include: design, content and delivery; referral mechanisms; choice of activity; qualifications and cost of instructors. Also identify any barriers preventing participation and factors that encourage it.

    doing some physical activity, albeit below current UK physical activity guidelines rather than none at all, should be taken into...

    Research recommendation
    Published
    9 June 2015

  2. 3C Patch for treating diabetic foot ulcers (HTG615)

    Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.

    HealthTech guidance
    Published
    7 March 2022
    View recommendations

    Sections for HTG615

  3. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

    Evidence summary
    Published
    24 February 2021

  4. Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

    Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.

    Technology appraisal guidance
    Published
    6 September 2023
    View recommendations

    Sections for TA913

  5. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.

    Technology appraisal guidance
    Published
    12 July 2017
    View recommendations

    Sections for TA455

  6. Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)

    Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA406

  7. MiraQ for assessing graft flow during coronary artery bypass graft surgery (HTG275)

    Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery.

    HealthTech guidance
    Last updated
    5 July 2022
    View recommendations

    Sections for HTG275

  8. Decreasing pharmacological treatment:- In adults, young people and children with well-controlled asthma, what are the objective measurements and prognostic factors that indicate that a decrease in regular maintenance treatment is appropriate?

    applicable) Why this is important:- There is consensus within the guideline committee and across healthcare professionals managing...

    Research recommendation
    Published
    18 October 2018

  9. Baseline FDG-PET-CT imaging for people with diffuse large B-cell lymphoma stage II or above:- In people with diffuse large B-cell lymphoma stage II or above, does a baseline FDG-PET-CT scan have any advantages over a baseline CT scan in the correct interpretation of the end-of-treatment FDG-PET-CT scan?

    notes(if applicable) Why this is important:- A number of consensus-based guidelines and a body of clinical opinion advocate baseline...

    Research recommendation
    Published
    25 August 2016

  10. Develop case identification tools for common mental health problems:- Develop or adapt reliable and valid tools for the case identification of common mental health problems in people with learning disabilities, for routine use in primary care, social care and education settings.

    problems in people with learning disabilities was a priority for this guideline.While case identification tools exist and are...

    Research recommendation
    Published
    17 October 2016

  11. Sorafenib for treating advanced hepatocellular carcinoma (TA474)

    Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

    Technology appraisal guidance
    Published
    6 September 2017
    View recommendations

    Sections for TA474

  12. QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

    NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .

    Medtech innovation briefing
    Published
    24 November 2020

  13. Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)

    NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .

    Medtech innovation briefing
    Published
    1 March 2022

  14. URO17 for detecting bladder cancer (MIB250)

    NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .

    Medtech innovation briefing
    Published
    4 February 2021

  15. What is the natural history of post-COVID-19 syndrome?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021